Weisheng Lu, Ph.D
Picture
Positions
- Postdoctoral Associate (Feb 2024 - now)
-
Pediatrics - Nutrition
Baylor College of Medicine
Houston, US
Addresses
- Children's Nutrition Research Center (Office)
-
1100 BATES
Room 8062
Houston, TX 77030
United States
- Children's Nutrition Research Center (Lab)
-
1100 BATES
Room 8052
Houston, TX 77030
United States
Education
- PharmD from China Pharmaceutical University
- 06/2021 - Nanjing, Jiangsu China
- BS from China Pharmaceutical Univeristy
- 06/2015 - Nanjing, Jiangsu China
Websites
Selected Publications
- Hsiao-Yun Lin†, Weisheng Lu†, Yanlin He, Yukiko Fu, Kentaro Kaneko, Peimeng Huang, Ana B. De la Puente-Gomez, Chunmei Wang, Yongjie Yang, Feng Li, Yong Xu, Makoto Fukuda* "Low-dose metformin requires brain Rap1 for its antidiabetic action." Sci Adv. 2025 Jul 30;11(31):eadu3700. Pubmed PMID: 40737402
- Kentaro Kaneko†, Weisheng Lu†, Yong Xu, Alexei Morozov, Makoto Fukuda* "The small GTPase Rap1 in POMC neurons regulates leptin actions and glucose metabolism." 2025 Feb 28;102117 Pubmed PMID: 40024570
- Weisheng Lu†, Hong Tian†, Peng Qian, Ying Li, Yongkang Wang, Yang Ge, Wenbo Sai, Xiangdong Gao*, Wenbing Yao* "An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice." Br J Pharmacol. 2020 Apr 15;177(15):3473-3488. Pubmed PMID: 32293707
- Teng Ma, Weisheng Lu, Yongkang Wang, Peng Qian, Hong Tian, Xiangdong Gao*, Wenbing Yao* "An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice." Eur J Pharmacol. 2022 Jan 5;914(174635) Pubmed PMID: 34800466
- Peng Qian†, Hong Tian†, Yongkang Wang, Weisheng Lu, Ying Li, Teng Ma, Xiangdong Gao*, Wenbing Yao* "A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction." Biochem Pharmacol. 2020 Dec;182(114209) Pubmed PMID: 32860826
Intellectual Property
- Oral hypoglycemic peptide, fatty acid derivative and use thereof
- Design Patent #WO2021027762A1 (Approved)
- Provided in the present invention are an oral hypoglycemic polypeptide, fatty acid modified derivatives thereof, and uses of the polypeptide and the fatty acid modified derivatives thereof.
- Co Inventors: GAO Xiangdong, TIAN Hong, LU Weisheng, YAO Wenbing, SAI Wenbo
Languages
Chinese (Mandarin), Japanese
Log In to edit your profile
